

# Hereditary Cancer Testing

A complete picture of your patient's disease includes their hereditary risk.

Tempus has partnered with Ambry Genetics® to provide germline testing. These tests are designed to specifically detect various germline variants associated with hereditary cancer syndromes.

➔ **xG (CancerNext®)**

36 gene panel associated with common hereditary cancer types analyzed by DNA sequencing.

➔ **xG+ (CancerNext-Expanded®)**

77 gene panel associated with both common and rare hereditary cancer types analyzed by DNA sequencing.

## ORDERING OPTIONS

- xG (CancerNext®) / xG+ (CancerNext-Expanded®) can be ordered as a standalone test or as a confirmatory test for potential germline findings from Tempus xT tumor + normal match sequencing, helping to possibly identify more patients at risk of hereditary cancer.
- Familial variant testing available for at-risk family members at no additional cost if ordered within 90 days of original xG (CancerNext®) / xG+ (CancerNext-Expanded®) report.
- Through one platform, somatic and germline testing can be ordered.
- Flexible ordering options via online ordering through Tempus Hub or paper requisition.


## REPORTING

- Reports include pathogenic and likely pathogenic variants as well as variants of uncertain significance. Amended reports are provided for variant reclassifications when available.
- Clinician management resources and patient guides are provided with reports when available.
- Results expected to be available approximately **14-21 days** after specimen receipt.
- Reports delivered through Tempus Hub or email/fax.

## SPECIMEN AND KIT REQUIREMENTS

- xG (CancerNext®) / xG+ (CancerNext-Expanded®) blood collection kit: 4ml lavender top EDTA tube.
- xG (CancerNext®) / xG+ (CancerNext-Expanded®) saliva collection kit: 1 Oragene (OGD-510) self-collection container.
- Cultured fibroblast specimens require completion of the additional Test Requisition for Tissue Culturing form.

*Samples will be sent to Ambry Genetics® using the dedicated Ambry collection kits.*



## Gene Lists

### xG+ (CancerNext-Expanded®) – 77 Genes:

AIP	ALK	APC	ATM	AXIN2	BAP1	BARD1	BLM
BMPR1A	BRCA1	BRCA2	BRIP1	CDC73	CDH1	CDK4	CDKN1B
CDKN2A	CHEK2	CTNNA1	DICER1	EGFR	EGLN1	EPCAM	FANCC
FH	FLCN	GALNT12	GREM1	HOXB13	KIF1B	KIT	LZTR1
MAX	MEN1	MET	MITF	MLH1	MSH2	MSH3	MSH6
MUTYH	NBN	NF1	NF2	NTHL1	PALB2	PDGFRA	PHOX2B
PMS2	POLD1	POLE	POT1	PRKAR1A	PTCH1	PTEN	RAD51C
RAD51D	RB1	RECQL	RET	SDHA	SDHAF2	SDHB	SDHC
SDHD	SMAD4	SMARCA4	SMARCB1	SMARCE1	STK11	SUFU	TMEM127
TP53	TSC1	TSC2	VHL	XRCC2			

### xG (CancerNext®) – 36 Genes:

APC	ATM	AXIN2	BARD1	BMPR1A	BRCA1	BRCA2	BRIP1
CDH1	CDK4	CDKN2A	CHEK2	DICER1	EPCAM	GREM1	HOXB13
MLH1	MSH2	MSH3	MSH6	MUTYH	NBN	NF1	NTHL1
PALB2	PMS2	POLD1	POLE	PTEN	RAD51C	RAD51D	RECQL
SMAD4	SMARCA4	STK11	TP53				

xG (CancerNext®) and xG+ (CancerNext-Expanded®) powered by Ambry Genetics® is available to select providers.

We help provide access to our tests for patients in financial need.

All Tempus tests, including xG/xG+, are eligible under the program. Patients can complete the application online at [access.tempus.com](https://access.tempus.com) or call [800.739.4137](tel:800.739.4137) to speak to a member of our team.

If you have any questions on our comprehensive portfolio of available tests, please contact your Tempus Representative or email [support@tempus.com](mailto:support@tempus.com)